The immunogenicity of the SARS-CoV-2 proteome is largely unknown, especially for non-
structural proteins and accessory proteins. In this study, we collect 2,360 COVID-19 sera and …

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …

Continual evolution of the severe acute respiratory syndrome coronavirus (SARS-CoV-2)
virus has allowed for its gradual evasion of neutralizing antibodies (nAbs) produced in …

In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with
antigenic changes in the spike protein are neutralized less efficiently by serum antibodies …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

The devastating economic and public health consequences caused by the COVID-19
pandemic have prompted outstanding efforts from the scientific community and …

SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million
infections and 1 million deaths since its emergence in December 2019. There are few …

Antibody cocktails represent a promising approach to prevent SARS-CoV-2 escape. The
determinants for selecting antibody combinations and the mechanism that antibody cocktails …

Abstract Development of antibody protection during SARS-CoV-2 infection is a pressing
question for public health and for vaccine development. We developed highly sensitive …